Mesa Laboratories (MLAB) Current Deferred Revenue (2013 - 2025)

Mesa Laboratories has disclosed Current Deferred Revenue across 13 years of filings, most recently posting $14.6 million for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $14.6 million, down 1.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $14.6 million (down 1.03% YoY), and the FY2025 annual result was $14.7 million, down 4.96% from the prior year.
• Current Deferred Revenue came in at $14.6 million for Q4 2025 at Mesa Laboratories, up from $14.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $16.3 million in Q3 2022 to a low of $8.8 million in Q1 2021.
• The 5-year median for Current Deferred Revenue is $14.6 million (2022), against an average of $14.0 million.
• Across the five-year window, Current Deferred Revenue soared 80.59% in 2021 and decreased 10.04% in 2023, its largest moves.
• Mesa Laboratories' Current Deferred Revenue stood at $13.8 million in 2021, then rose by 5.62% to $14.6 million in 2022, then decreased by 1.56% to $14.4 million in 2023, then gained by 2.46% to $14.7 million in 2024, then decreased by 1.03% to $14.6 million in 2025.
• The last three Current Deferred Revenue figures came in at $14.6 million (Q4 2025), $14.3 million (Q3 2025), and $15.1 million (Q2 2025), per Business Quant data.